Evidence Level
Cat's Claw has a well-documented history in traditional Amazonian medicine and is increasingly supported by clinical evidence. A randomized double-blind trial conducted by Mur et al. (2002) demonstrated that a 60mg/day POA-standardized extract significantly reduced painful and swollen joints in patients with rheumatoid arthritis who were already on sulfasalazine. For osteoarthritis, Piscoya et al. (2001) reported rapid pain relief within one week using freeze-dried Cat's Claw. Mechanistically, pentacyclic oxindole alkaloids inhibit NF-kB and suppress TNF-alpha production, contributing to its anti-inflammatory effects.
A systematic review by Arado et al. (2024) of 24 studies highlighted that Uncaria tomentosa extracts reduced IL-6 and NF-κB in animal models of inflammation. Additionally, Lopes et al. (2025) found that Cat's Claw extracts, particularly those rich in POA, exhibited selective cytotoxicity against certain cancer cells in vitro. However, a systematic review by Rosenbaum et al. (2010) noted limited evidence supporting its use for osteoarthritis and rheumatoid arthritis compared to other supplements.
Key distinctions exist between pentacyclic (anti-inflammatory) and tetracyclic (immune-stimulating) alkaloid chemotypes, emphasizing the importance of specifying POA content in quality products. While promising, more large-scale clinical trials are needed to establish definitive efficacy across various conditions.